Neudle.com: cytoprotective agents

Differential
(Click to cross reference)

activities of daily living

advances in neurology

adverse drug reaction

Alzheimer's disease, preclinical

Alzheimer's disease, risk factors in

Alzheimer's disease, treatment of

amyloid beta protein

amyotrophic lateral sclerosis

amyotrophic lateral sclerosis, differential diagnosis

amyotrophic lateral sclerosis, etiology of

amyotrophic lateral sclerosis, prognosis

amyotrophic lateral sclerosis, treatment of

aneurysm

aneurysm, intracranial

aneurysm, intracranial, delayed cerebral ischemia with

aneurysm, intracranial, treatment of

angiotensin II receptor blocker

antibiotics

anticoagulant, treatment

anticoagulant, treatment in CVD

atherosclerosis, generalized

autonomic dysfunction

brain transplantation

bulbar palsy

bulbar palsy, progressive

burning paresthesia

caffeine

calcium antagonist

calcium antagonist, side effects of

cardiac arrest

cardiac arrest and resuscitation

caspases

CAT scan

CAT scan, abnormal

CAT scan, disappearing lesion on

CAT scan, emission

CAT scan, emission, abnormal

CAT scan, xenon-enhanced

cerebrovascular accident

cerebrovascular accident, acute management of

cerebrovascular accident, complications with

cerebrovascular accident, neonatal

cerebrovascular accident, pathophysiology

cerebrovascular accident, prevention of

cerebrovascular accident, prognosis in

cerebrovascular accident, severity

cerebrovascular accident, spontaneous improvement after

cerebrovascular accident, surgical treatment of

cerebrovascular accident, thrombolytic agents in treatment

cerebrovascular accident, time of presentation

cerebrovascular accident, volume

cerebrovascular accident, work up for

cerebrovascular disease

cerebrovascular disease, risk factors in

cerebrovascular disease, surgical treatment of

controversies in neurology

cooling therapy

coronary artery disease

craniectomy, decompressive

crying, pathologic

DATATOP study

degenerative diseases of CNS

dementia

dementia, prevention of

dementia, treatment of

deprenyl

diet

dimebon

disability, neurological

distal muscle weakness

dopamine agonist

dopamine receptor, D2

drug induced neurologic disorders

dying

dysarthria

dyskinesia, buccal lingual facial

dysphagia

efficacy

embolism

emergencies, neurologic

emergency medical technicians

emotional lability

encephalopathy, post traumatic

endarterectomy, carotid

endarterectomy, carotid-complications of

endarterectomy, carotid-indications for

endarterectomy, carotid-long term results

endarterectomy, carotid-morbidity and mortality with

endovascular therapy

enzyme inhibition

epidemiology of neurology

fibrinolytic agents, combined IA and IV

fibrinolytic agents, contraindications

fibrinolytic agents, intra-arterial local infusion

fibroblast growth factor

head injury, evaluation of

head injury, management of

head injury, pathophysiology of

head injury, prevention

head injury, prognosis in

headache

headache, treatment of

hemodilution

hemorrhage, intracranial, newborn

hemorrhage, periventricular

heparin

heralding manifestation

herpes simplex encephalitis, diagnosis of

histamine-2 receptor blockers

HMGcoA reductase inhibitors

hypotension, systemic

hypothermia

hypoxic encephalopathy

iatrogenic neurologic disorders

intracranial pressure monitoring

intraventricular hemorrhage

intrinsic hand muscles, wasting of

ischemic penumbra

Kleine-Levin syndrome

lacunar infarction

laughing, pathologic

L-dopa

leg weakness, unilateral

Lewy body

Lewy body disease, diffuse

mental status, evaluation of

middle cerebral artery, occlusion of

migraine, prophylaxis

migraine, treatment of

mild cognitive impairment

minocycline

monoamine oxidase inhibitors

mortality

motor neuron disease

movement disorder, extrapyramidal

MRI

MRI, abnormal

MRI, CAT scan compared to

MRI, cerebrovascular disease

MRI, contrast enhanced

MRI, diffusion weighted

MRI, early changes in CVA

MRI, false negative

MRI, mismatch between perfusion/diffusion

MRI, perfusion

MRS

multiple sclerosis

multiple sclerosis, monosymptomatic

multiple sclerosis, pathogenesis

multiple sclerosis, relapsing

multiple sclerosis, treatment of

multiple sclerosis, treatment of, first attack

muscle wasting, diffuse

N-acetyl-L-aspartic acid

nerve growth factor

neuroendocrinology

neurologic disease

neurologic disease, diagnoses of

neurologic evaluation

neurologic examination

neuropathology, brain

neuropathy

neuroprotective agents

nonsteroidal anti-inflammatory drug

old age, neurology of

Parkinson disease, diagnosis

Parkinson disease, drug induced

Parkinson disease, early symptoms

Parkinson disease, etiology of

Parkinson disease, nonmotor problems of

Parkinson disease, pathogenesis of

Parkinson disease, prognosis of

Parkinson disease, progression

Parkinson disease, surgical treatment of

Parkinson disease, treatment of

Parkinsonism syndrome

pathology

pineal

piracetam

platelet inhibiting drugs

prevention of neurologic disorders

prognosis

psychological testing

rasagiline

rehabilitation for neurologic disorders

risk-benefit assessment

safety

seizure

seizure, treatment of

simvastatin

sinemet

single photon emission computed tomography

sleep

sleep pathology and physiology

stroke, progression of

subarachnoid hemorrhage

subarachnoid hemorrhage, treatment of

subthalamic nucleus

subthalamic nucleus deep brain stimulation

synucleinopathy

tea

tetracycline

thrombolysis, mechanical

tissue plasminogen activator, intravenous

treatment of neurologic disorder

tremor, thalamic stimulation for suppression of

tripping

vasospasm, cerebral

vegetables

vestibular function, tests of

vitamin A

vitamin D

vitamin E

vitamin supplementation

whites

wine

Showing articles 50 to 100 of 3373 << Previous Next >>

Estrogen-replacement Therapy and Alzheimer's disease in the Italian Longitudinal Study on Aging
Neurol 50:996-1002, Baldereschi,M.,et al, 1998

Combating Hyperthermia in Acute Stroke, A Significant Clinical Concern
Stroke 29:529-534, Ginsberg,M.D.&Busto,R., 1998

Duration of Neuroprotective Treatment for Ischemic Stroke
Stroke 29:535-542, Dyker,A.G.&Lees,K.R., 1998

Lubeluzole Treatment of Acute Ischemic Stroke
Stroke 28:2338-2346, Grotta,J., 1997

A Prospective Study of Estrogen Replacement Therapy and the Risk of Developing Alzheimer's Disease
Neurol 48:1517-1521, Kawas,C.,et al, 1997

Dietary Antioxidants and Parkinson Disease
Arch Neurol 54:762-765, deRijk,M.C.,et al, 1997

Characterizing the Target of Acute Stroke Therapy
Stroke 28:866-872, Fisher,M., 1997

Progression of Ischaemic Stroke and Excitotoxic Aminoacids
Lancet 349:79-83, Castillo,J.,et al, 1997

Risk of Alzheimer's Disease and Duration of NSAID Use
Neurol 48:626-632, Stewart,W.F.,et al, 1997

Treatment of Acute Ischemic Stroke with Piracetam
Stroke 28:2347-2352, DeDeyn,P.P.,et al, 1997

Melatonin"A Clinical Perspective
Ann Neurol 42:545-553, Penev,P.D.,et al, 1997

Dietary Flavonoids, Antioxidant Vitamins, and Incidence of Stroke
Arch Int Med 154:637-642, Keli,S.O.,et al, 1996

Arthritis & Anti-Inflammatory Agents as Possible Protective Factors for Alzheimer's Dis:Review of 17 Epidemiologic Studies
Neurol 47:425-432, McGeer,P.L.,et al, 1996

Dose-Ranging Study of Riluzole in Amyotrophic Lateral Sclerosis
Lancet 347:1425-1431, Lacomblez,L.,et al, 1996

Selegiline and Mortality in Parkinson's Disease
Ann Neurol 40:841-845, Olanow,C.W.,et al, 1996

Routine Indomethacin Prophylaxis:Has the Time Come
Pediatrics 98:784-785, Bada,H.S., 1996

Lubeluzole in Acute Ischemic Stroke:A Double-Blind Placebo-Controlled Phase II Trial
Stroke 27:76-81, Diener,H.C.,et al, 1996

Impact of Deprenyl and Toxopherol Treatment on Parkinson's Disease in DATATOP Subjects Not Requiring Levodopa
Parkinson Study Group, Ann Neurol 39:29-361996., , 1996

Impact of Deprenyl and Toxopherol Treatment on Parkinson's Disease in DATATOP Patients Requiring Levodopa
Parkinson Study Group, Ann Neurol 39:37-451996., , 1996

The Relation Between Fish Consump & Stroke Incidence, NHANES I Epidemiol Study
Arch Int Med 156:537-542, Gillum,R.F.,et al, 1996

A 60-Year-Old Man with Parkinson's Disease
JAMA 275:716-722, Olanow,C.W., 1996

Cognitive Impairment & Mortality in a Cohort of Elderly People
BMJ 312:608-611, Gale,C.R.,et al, 1996

The Effect of Deprenyl and Levodopa on the Progression of Parkinson's Disease
Ann Neurol 38:771-777, Olanow,C.W.,et al, 1995

Comparison of Therapeutic Effects & Mortality Data of Levodopa & Levodopa with Selegiline in Pts with Early, Mild Parkinson's
BMJ 311:1602-1607, 15831995., Lee,A.J.,et al, 1995

Cigarette Smoking and Protection from Parkinson's Disease:False Association or Etiologic Clue?
Neurol 45:1041-1051, Morens,D.M.,et al, 1995

Head Injury
JNNP 58:526-539, Teasdale,G.M., 1995

Clinical Experience with Excitatory Amino Acid Antagonist Drugs
Stroke 26:503-513, Muir,K.W.&Lees,K.R., 1995

Prophylactic Neuroprotection for Cerebral Ischemia
Stroke 25:1075-1080, Fisher,M.,et al, 1994

Guidelines for the Management of Patients with Acute Ischemic Stroke
Stroke 25:1901-1914, Adams,H.P.,et al, 1994

The Ischemic Penumbra, Injury Thresholds, and the Therapeutic Window for Acute Stroke
Ann Neurol 36:553-554, 5571994., Ginsberg,M.D.&Pulsinelli,W.A., 1994

Growth Factors:Potential Therapeutic Applications in Neurology
JNNP 54:1445-1450, Drago,J.,et al, 1994

A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis
NEJM 330:585-591, Bensimon,G.,et al, 1994

A Randomized, Double-Blind, Placebo-Controlled Trial of Nimodipine in Acute Ischemic Hemispheric Stroke
Stroke 25:1348-1353, Kaste,M.,et al, 1994

Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
The Parkinson Study Group, NEJM 328:176-1831993., , 1993

Head Injury
JNNP 56:440-447, Miller,J.D., 1993

Treatment of Parkinson's Disease
NEJM 329:1021-1027, Calne,D.B., 1993

Evolving Toward Effective Therapy for Acute Ischemic Stroke
JAMA 270:360-364, Fisher,M.&Bogousslavsky,J., 1993

The Free Radical Hypothesis in Idiopathic Parkinsonism:Evidence Against It
Ann Neurol 32:799-803, Calne,D.B., 1992

Clinical Trial of Nimodipine in Acute Ischemic Stroke
The American Nimodipine Study Group, Stroke 23:3-81992., , 1992

Pathophysiology of Acute Ischaemic Stroke
Lancet 339:533-536, Pulsinelli,W., 1992

Serum Concentrations of Vitamins A and E and Early Outcome after Ischaemic Stroke
Lancet 339:1562-1565, DeKeyser,J.,et al, 1992

Do NMDA Antagonists Prevent Neuronal Injury? Yes
ARch Neurol 49:418-420, Albers,G.W.,et al, 1992

Do NMDA Antagonists Prevent Neuronal Injury? No
Arch Neurol 49:420-421, Buchan,A.M., 1992

Tissue Plasminogen Activator Plus Glutamate Antagonist Improves Outcome after Embolic Stroke
Arch Neurol 48:1235-1238, Zivin,J.A.&Mazzarella,V., 1991

The Bioloigcal Basis for the Treatment of Acute Stroke
Neurol 41:1867-1873, Scheinberg,P., 1991

Early Treatment of Ischemic Stroke with a Calcium Antagonist
Stroke 22:437-441, Rosenbaum,D.,et al, 1991

Calcium Antagonists:Stroke Therapy Coming of Age
Stroke 21:494-501, Wong,M.C.W.&Haley,E.C., 1990

Restorative Neurology, Drugs and Recovery Following Stroke
Stroke 21:1636-1640, Goldstein,L.B.&Davis,J.N., 1990

DATATOP:A Multicenter Controlled Clinical Trial in Early Parkinson's Disease
Parkinson Study Group, Arch Neurol 46:1052-10601989., , 1989

Effect of Nimodipine on Cerebral Infarction & Outcome after Subarachnoid Haemorrhage:British Aneurysm Nimodipine Trial
BMJ 298:636-642, Pickard,J.D.,et al, 1989

Showing articles 50 to 100 of 3373 << Previous Next >>